Intellia Therapeutics, Inc. (NTLA)
About Intellia Therapeutics, Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $67.7M
- Net income
- -$412.7M
- Total assets
- $842.1M
- Market cap
- $1.9B
- Operating margin
- -651.7%
- Net margin
- -609.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $67.7M
- Operating expenses
- $508.7M
- Operating income
- -$441.0M
- Income tax
- $0
- Net income
- -$412.7M
- EPS (basic)
- $-3.81
- EPS (diluted)
- $-3.81
Balance sheet
- Total assets
- $842.1M
- Current assets
- $527.7M
- Total liabilities
- $170.7M
- Current liabilities
- $103.9M
- Shareholders’ equity
- $671.4M
Cash flow
- Operating cash flow
- -$394.7M
- Investing cash flow
- $228.0M
- Financing cash flow
- $131.5M
- Net cash flow
- -$35.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-3.81
- Shares outstanding
- 176.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 6, 2016
Intellia Therapeutics, Inc. (NTLA) Stock Price
- Reported a net loss of $412.7M in FY2025.
- Revenue grew 17% from FY2020 to FY2025.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Intellia Therapeutics, Inc..
Write a review
News about Intellia Therapeutics, Inc.
News & sentiment via Polygon.io
Intellia Therapeutics, Inc.: frequently asked questions
Is Intellia Therapeutics, Inc. an American company?
Intellia Therapeutics, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Intellia Therapeutics, Inc. publicly traded?
Yes — Intellia Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol NTLA on the NASDAQ.
What does Intellia Therapeutics, Inc. do?
Intellia Therapeutics, Inc. is an American Medical Devices company in the Health & Beauty sector.
